VAXCYTE INC. - COMMON STOCK

Vaxcyte Provides Positive Regulatory Updates on VAX-31 Pediatric and Adult Programs

12 Nov 2024 06:30:11 By Nasdaq GlobeNewswire

Vaxcyte Reports Third Quarter 2024 Financial Results and Provides Business Update

05 Nov 2024 15:01:35 By Nasdaq GlobeNewswire

Vaxcyte to Present at the 2024 Cantor Global Healthcare Conference

11 Sep 2024 15:05:03 By Nasdaq GlobeNewswire

Vaxcyte Announces Closing of $1.5 Billion Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares

06 Sep 2024 15:05:46 By Nasdaq GlobeNewswire

Vaxcyte Announces Pricing of $1.3 Billion Public Offering

04 Sep 2024 22:58:41 By Nasdaq GlobeNewswire

Vaxcyte Announces Commencement of Proposed Public Offering of Common Stock and Pre-Funded Warrants

03 Sep 2024 15:01:32 By Nasdaq GlobeNewswire

Vaxcyte Reports Positive Topline Data from Phase 1/2 Study of VAX-31, its 31-Valent Pneumococcal Conjugate Vaccine Candidate, in Adults Aged 50 and Older

03 Sep 2024 06:07:43 By Nasdaq GlobeNewswire

Vaxcyte to Host Webcast and Conference Call to Present Topline Results from Phase 1/2 Study of VAX-31, its 31-Valent Pneumococcal Conjugate Vaccine Candidate, in Adults Aged 50 and Older

02 Sep 2024 17:40:59 By Nasdaq GlobeNewswire

Vaxcyte Reports Second Quarter 2024 Financial Results and Provides Business Update

06 Aug 2024 15:05:01 By Nasdaq GlobeNewswire

Vaxcyte Appoints John Furey to Board of Directors

02 Jul 2024 07:30:00 By Nasdaq GlobeNewswire

Vaxcyte Reports First Quarter 2024 Financial Results and Provides Business Update

08 May 2024 15:05:00 By Nasdaq GlobeNewswire

Vaxcyte to Present at the 23rd Annual Needham Virtual Healthcare Conference

02 Apr 2024 15:05:51 By Nasdaq GlobeNewswire

Vaxcyte Completes Enrollment of Phase 2 Study Evaluating VAX-24 for the Prevention of Invasive Pneumococcal Disease (IPD) in Infants

04 Mar 2024 07:30:00 By Nasdaq GlobeNewswire

Vaxcyte Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

27 Feb 2024 15:01:00 By Nasdaq GlobeNewswire

Vaxcyte to Report Fourth Quarter and Full Year 2023 Financial Results on February 27, 2024

15 Feb 2024 15:05:00 By Nasdaq GlobeNewswire

Vaxcyte Announces Closing of $862.5 Million Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares

02 Feb 2024 17:39:14 By Nasdaq GlobeNewswire

Vaxcyte to Present at the Guggenheim Healthcare Talks | 6th Annual Biotechnology Conference

01 Feb 2024 15:05:49 By Nasdaq GlobeNewswire

Vaxcyte Announces Pricing of $750 Million Public Offering

30 Jan 2024 22:37:41 By Nasdaq GlobeNewswire

Vaxcyte Announces Commencement of Proposed Public Offering of Common Stock and Pre-Funded Warrants

30 Jan 2024 15:01:28 By Nasdaq GlobeNewswire

Vaxcyte Completes Enrollment of Phase 1/2 Study Evaluating VAX-31 for the Prevention of Invasive Pneumococcal Disease (IPD) in Adults Aged 50 and Older

29 Jan 2024 07:30:33 By Nasdaq GlobeNewswire